Venture capital investor BayBG Bayerische Beteiligungsgesellschaft mbH has invested an undisclosed amount in CANDOR Bioscience GmbH, a supplier and service provider for GLP laboratories and pharmaceutical industry. The company will use the new capital to fund further growth, especially focusing on expanding its production capacity.
PayPoint will use the proceeds to focus on core UK markets
Round for the biotechnology company extends the CHF 2.5m August 2019 round led by Redalpine
UnternehmerTUM Fonds III has a target of €150m and will focus on series-A and early-stage rounds
Deal is HTGF's 11th exit during the coronavirus pandemic, and comes seven years after the VC first invested in the company